The cancer biotherapy research group [CBRG], formerly the National Biotherapy Study Group [NBSG]: A 10-year perspective

Cancer Biotherapy and Radiopharmaceuticals

Volumn 12, Issue 4, 1997, Pages 229-242

  Dillman, Robert O ^a,d   Crispin, Rosalie ^b   Oldham, Robert K ^c  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^b Central Office of the CBRG   (United States)

^c Biological Therapy Institute   (United States)

^d Cancer Biotherapy Research Group   (United States)

Author keywords

Biotherapy; Cancer; Cancer research; Clinical trials; Cooperative group

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; COLONY STIMULATING FACTOR; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MACROGOL; OKT 3; TUMOR NECROSIS FACTOR; TUMOR VACCINE;

ARTICLE; BIOLOGICAL THERAPY; BIOTECHNOLOGY; CANCER RESEARCH; CANCER THERAPY; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG APPROVAL; FINANCE; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; MEDICAL LITERATURE; MEDICAL SOCIETY; MELANOMA; OVARY CANCER; PRIORITY JOURNAL;

EID: 0031472548     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1997.12.229     Document Type: Article

References (71)

1. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with melastatic cancer N Engl J Med 1985; 313:1485-1492.
2. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DE, Thurman GB, Oldham RK. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer N Engl J Med 1987;316:898-905.
3. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-897.
4. Durant JR. Immunotherapy of cancer: the end of the beginning? N Engl J Med 1987;316:939-940
5. Moertel CG. On lymphokines, cytokines, and breakthroughs JAMA 1986;256:3141.
6. Yannelli JR, Thurman GB, Dickerson SB, Mrowca A, Sharp E, Oldham RK. An improved method for the generation of human lymphokine activated killer cells. J Immunol Meth 1987,100:1137-145.
7. Yannelli JR, Thurman GB, Mrowca-Bastin A, Pennington CS, West WH, Oldham RK. Enhancement of human lymphokine-activated killer cell cytolysis and a method for increasing lymphokine-activated killer cell yields to cancer patients. Cancer Res 1988;48:5696-7500.
8. Maleckar JR, Friddell CS, Sferruzza A, Thurman GB, Lewko WM, West WH et al. Activation and expansion of tumor derived activated cells for therapeutic use. J Natl Cancer Inst 1989,81:1655-1660.
9. Yannelli JR, Crumpacker DB, Good RW, Friddell CD, Poston R, Horton S, et al. Use of anti-CD3 in the generation of effector cells from human solid tumors for use in the biotherapy of cancer. J Immunol Meth 1990;1:91-100.
10. Horton SA, Oldham RK, Yannelli JR. Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin-2. Cancer Res 1990; 50:1686-1692.
11. West WH, Tauer KW, Yannelli JR, Marshall GC, Orr DW, Lewis M, et al. Multiple cycles of constant-infusion recombinant interleukin-2 in adoptive cellular therapy of metastatic renal cell carcinoma. Molec Biother 1989;1:2268-274.
12. Dillman RO, Oldham RK, Tauer KW, Orr DW, Barth NM, Blumenschein G, et al. Continuous interleukin-2 and lymphokine activated killer cells for advanced cancer: anNBSG trial. J Clin Oncol 1991;9:1233-1240.
13. Dillman RO, Oldham RK, Barth NM, Birch R, Arnold J, West WH. Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma; an NBSG trial. J Natl Cancer Inst 1990; 82:1345-1352.
14. Dulman RO, Oldham RK, Barth NM, Cohen RE, Minor DR, Birch R, et al. Continuous interleukin-2 and tumor infiltrating lymphocytes as treatment of advanced melanoma; a National Biotherapy Study Group trial. Cancer 1991;68:1-8.
15. Oldham RK, Stark J, Barth NM, Hoogstraten B, Brown CH, O'Connor T, et al. Continuous infusion interleukin-2 and cyclophosphamide as treatment of advanced cancer, an NBSG trial. Molec Biother 1991,3:74-78.
16. Oldham RK, Dillman RO, Yannelli JR, Barth NM, Maleckar JR, Sferruzza A, et al. Continuous infusion interleukin-2 and tumor derived activated cells as treatment of advanced solid tumors. A National Biotherapy Study Group Trial. Mol Biother 1991;3:68-73.
17. Oldham RK, Blumenschein G, Schwartzberg L, Birch R, Arnold J. Combination biotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer: a National Biotherapy Study Group Trials. Molec Biother 1992;4:4-9.
18. Schwartzberg L, West WH, Birch R, Oldham RK, Orr DW, Kalman L. Phase II study of recombinant tumor necrosis factor (rTNF) and recombinant interleukin-2 (rIL-2) in advanced malignancies. Proc Am Soc Clin Oncol 1990;9:191(abstr 738).
19. Dillman RO, Church C, Oldham RK, West WH, Schwartzberg L, Birch R. Experience with high-dose continuous interleukin-2 in the treatment of 788 cancer patients. Cancer 1993;71:2358-2370.
20. Dillman RO, Oldham RK, Church C, Sowell M. Survival of patients with metastatic cancer for more than three years after starting continuous infusion IL-2 therapy in trials of the National Biotherapy Study Group. J Immunother 1995;18:129
21. Dillman RO, Church C, Barth NM, Oldham RK, Wiemann MC. Long-term, survival after continuous infusion interleukin-2 in trials of the Cancer Biotherapy Research Group. Cancer Biother 1997. [in press]
22. Dillman RO. Monoclonal antibodies for treating cancer. Ann Intern Med 1989;111 592-603.
23. Dillman RO, Johnson DE, Ogden JR, Beidler D. Significance of antigen, drug and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates. Molec Biother 1989;1:250-255.
24. Avner B, Avner BP, Gaydos B, Liao S-K, Thurman GB, Oldham RK. Characterization of a method using viable human target cells as the solid phase in a cell concentration fluorescence immunoassay (CCFIA) for screening of monoclonal antibodies and hybridomas. J Immunol Meth 1988;113:123-135.
25. Avner BP, Liao S-K, Avner B, DeCell K, Oldham RK. Therapeutic murine monoclonal antibodies developed for individual cancer patients. J Biol Response Mod 1989;8:25-36.
26. Liao S-K, Meranda C, Avner BP, Romano T, Husseini S, Kimbro B, Oldham RK. Immunohistochemical phenotyping of human solid tumors with monoclonal antibodies in devising biotherapeutic strategies. Cancer Immunol Immunother 1989;28:77-86.
27. Ogden JR, Leunk K, Kunda SA, Telander MW, Avner BP, Liao S-K, et al. Immunoconjugates of doxorubicin and murine antihuman breast carcinoma monoclonal antibodies prepared via an N-hydroxysuccinimide active ester intermediate of cis-aconityl-doxorubicin: preparation and in vitro cytotoxicity. Molec Biother 1989; 1:170-174.
28. Oldham RK, Lewis M, Orr DW, Avner B, Liao S-K, Ogden JR, et al. Adriamycin custom-tailored immunoconjugates in the treatment of human malignancies. Molec Biother 1988;1:103-113.
29. Orr DW, Oldham RK, Lewis M, Ogden J, Liao S-K, Leung K, et al. Phase I trial of mitomycin-C immunoconjugate cocktails in human malignancies. Molec Biother 1989;1:229-240.
30. Oldham RK. Custom-tailored drug unmunoconjugates in cancer therapy. Molec Biother 1991;3:148-162.
31. Bett CB, Carbone PP, Elson PJ, Elson MS, Zelen M. Participation of community hospitals in clinical trials: analysis of five years of experience in the Eastern Cooperative Oncology Group. N Engl J Med 1982; 306:1076-1080.
32. Einstein AB, Keller AM, Coltman CA, Fisher B, DeCillis, et al. Clinical research in the community. Oncol Issues 1994;9:12-20.
33. Cobau CD. Clinical trials in the community: the community clinical oncology program experience. Cancer 1994,74(suppl):2694s-2700s.
34. Avent RA, Dillman RO. Cancer clinical trials in the community setting: a 20 year retrospective. Cancer Biother 1995;10:95-113.
35. Lind SE. Sounding board: fee-for-service research. N Engl J Med 1986;314:312-314.
36. Oldham RK. Sounding board: patient-funded cancer research. N Engl J Med 1987; 316:46-47.
37. Schwartzberg L, West WH, Fyfe G, Tauer K, Zimmerman R, Arnold JA. A phase I study of recombinant interleukin-2 (rIL-2) in advanced malignancy: modification of dosing to emulate the pharmacokinetics of polyethylene glycol-modified rIL-2 (PEG rIL-2). Proc Am Soc Clin Oncol 1991;10:93 (abstr 241).
38. Soori GS, Oldham RK, Dobbs TW, Hall DJ, Bury MJ, Barth NM, Dillman RO, et al. 5-fluorouracil, mitomycin-C, leucovorin and α-interferon in metastatic adenocarcinoma of the pancreas, stomach, and esophagus. Proc Am Soc Clin Oncol 1995;14:224 [abstr 575]
39. Soori GS, Oldham RK, Dobbs TW, Stark JJ, Bury MJ, DePriest C. Chemo-biotherapy with 5-fluorouracil, leucovorin and alpha interferon in patients with metastatic adenocarcinoma of the colon. J Immunother 1995;18:128.
40. Soori GS, Oldham RK, Dobbs TW, Bury MJ, Block M, Dillman RO, et al. Chemo-biotherapy with 5-fluorouracil, leucovorin, mitomycin-C and alpha interferon in metastatic adenocarcinoma of the pancreas. J Immunother 1995;18:128.
41. Stark JJ, Dillman RO, Schulof R, Wiemann M, Barth NM, Honeycutt PJ, Soori G. Interferon-α and chemohormonal therapy in advanced melanoma: final results of a phase I-II study of the National Biotherapy Study Group and the Mid-Atlantic Oncology Program. [manuscript submitted]
42. Soori G, Schulof R, Stark J, Wiemann M, Honeycutt P, Arnold J, Church C. Phase II trial of continuous infusion floxuridine (FUDR) and interferon-alpha-2b in advanced renal cancer - an NBSG study. Proc Am Soc Clin Onc 1993;12:236 (abstr 731).
43. Dillman RO, Wiemann M, Oldham RK, Soori G, Bury M, Hafer R, et al. Interferon α-2a and external beam radiotherapy in the initial management of patients with glioma: a pilot study of the National Biotherapy Study Group. Cancer Biother 1995;10:265-271.
44. Dillman RO, Barth NM, Mahdavi K, VanderMolen LA, Nayak SK, O'Connor A. The integration of high-dose chemotherapy and biotherapy: initial 5-year experience with autologous bone marrow transplantation in a comprehensive community cancer center. Cancer Biother 1995;10:25-36.
45. Dillman RO, Barth NM, Nayak SK, DeLeon C, O'Connor, Morrelli L. High-dose chemotherapy with autologous stem cell rescue in breast cancer. Breast Cancer Res Treat 1996;37:277-289.
46. Dillman RO, Barth NM, VanderMolen LA, Mahdavi K, Nayak SK. Single institution experience with high-dose chemotherapy and autologous stem cell rescue in hematologic malignancies. Blood 1996,88(suppl 1):228b (abstr 3856).
47. Dillman RO, Barth NM, VanderMolen L, Nayak SK, O'Connor A, Beutel L, Morrelli L High-dose chemotherapy and peripheral blood stem cell rescue in breast cancer Breast Cancer Res Treat 1996,41:278 (abstr 421).
48. Nayak DK, Dillman RO. Establishment of multiple tumor cell lines from a patient with melanoma: a simple method to control fibroblast growth. Clin Biotechnol 1991;3:237-242.
49. Dillman RO, Nayak SK, Beutel L. Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J Immunother 1993,14:65-69.
50. Nayak SK, McCallister T, Han LJ, Gangavalli R, Barber J, Dillman RO. Transduction of human renal carcinoma cells with human γ-interferon gene via retroviral vector. Cancer Gene Ther 1996;3 143-150.
51. Dillman RO, Nayak SK, Johnson D, Brown J, Chico S. The potential to use short-term cultures of ovarian cancer cells as autologous tumor cell vaccines. Proc Am Assoc Clin Res 1997;38:45
52. Dillman RO, Nayak S, Barth N, Wiemann M, DeLeon C. Irradiated, cultured, autologous tumor cells for active specific immunotherapy. Proc Am Soc Clin Oncol 1995; 14:546 (abstr 1810).
53. Dillman RO, Nayak SK, Barth NM, DeLeon C, Schwartzberg L, Spitler L, et al. Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma. [manuscript submitted for publication].
54. Nayak SK, Beutel L, Irani S, Dillman RO. Characterization of autologous activated lymphocytes being used for adoptive immunotherapy of cancer. Proc Am Assoc Cancer Res 1995;36:481 [abstr 2864].
55. Dillman RO, Nayak SK, O'Connor A, DePriest C, Church C. Phase I-II trial of autologous activated lymphocytes in the treatment of metastatic cancer. J Immunother 1995;17:125.
56. Goolsby T, Oldham RK, Sharp E, Lewko W, Good R. Interleukin-2 and bioreactor grown tumor-derived activated T cells (TDAC) in the treatment of cancer. Proc Am Soc Clin Oncol 1994;13:302 [abstr 986]
57. Lewko WM, Good RW, Bowman D, Smith T, Oldham RK. Growth of tumor derived activated T-cells for the treatment of cancer. Cancer Biother 1994,9:211-224.
58. Nayak SK, Beutel L, Irani S, Dillman RO. Growth of human tumor infiltrating lymphocytes in tissue culture for use in adoptive cellular immunotherapy. J Immunother 1994;16:242.
59. Forrest DB, Han LJ, Nayak SK, Dillman RO. Clonal analysis of tumor infiltrating lymphocytes expanded for biological therapy. Proc Am Assoc Cancer Res 1994; 35:498 [abstr 2968].
60. Nayak SK, Beutel L, Irani S, Dillman RO. Human tumor infiltrating lymphocytes for adoptive cellular immunotherapy. Proc Am Assoc Cancer Res 1995; 36:481 [abstr 2865].
61. Schiltz PM, Dillman RO, Beutel L, Nayak SK. Characterization of human tumor infiltrating lymphocytes expanded in a hollow fiber bioreactor and used for adoptive immunotherapy of cancer. J Immunother 1996; 19:462.
62. Schiltz PM, Beutel LD, Nayak SK, Dillman RO. Characterization of tumor infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer. J Immunother [in press]
63. Dillman RO, Hurwitz R, Schiltz PM, Barth NM, Beutel LD, Nayak SK, O'Connor AA. Tumor localization by tumor infiltrating lymphocytes labeled with indium-111 in patients with metastatic renal cell carcinoma, melanoma, and colorectal cancer. Cancer Biother 1997; 12:65-71.
64. Oldham RK, Goolsby T, Sharp E. Interleukin-2 and "pulse" LAK cells in the treatment of cancer. Proc Am Soc Clin Oncol 1994;13:301 [abstr 985]
65. Oldham RK, Reid WK. Interleukin-2 and "pulse" LAK cells in the treatment of cancer. Proc Am Soc Clin Oncol 1997;16:442a [abstr 1586]
66. Dillman RO, Wiemann MC, Bury MJ, Church C, DePriest C. Hybrid high-dose/continuous infusion interleukin-2 in patients with metastatic renal cell carcinoma: a phase II trial of the National Biotherapy Study Group. Cancer Biother 1997;12:5-11.
67. Dillman RO, Wiemann MC, VanderMolen LA, Bury MJ, DePriest C, Church C. Hybrid high-dose bolus/continuous infusion interleukin-2 m patients with metastatic melanoma, a phase II trial of the National Biotherapy Study Group. [Manuscript submitted for publication].
68. Soori G, Stark JJ, Wiemann MC, Honeycutt PJ, Cogbum BE, Tai DF, et al. Outpatient phase II trial of alpha interferon, subcutaneous interleukin-2, 5-fluorouracil, and cis-retinoic acid in patients with metastatic renal cell cancer. Proc Am Soc Clin Oncol 1997;16:344a [abstr 1231].
69. Honeycutt P, Wiemann M, Bury M, Soori G, Dobbs TW, Granick J et al. Phase II trial of BCNU, DTIC, cisplatin, tamoxifen and outpatient interleukin-2 and interferon-α in the treatment of metastatic melanoma. Proc Am Soc Clin Oncol 1997;16:506a [abstr 1819]
70. Schiltz PM, Malone C, Dillman RO, Shea WM, Nayak SK. Interferon-α-2a combined with 13-cis-retinoic acid treatment produces enhanced radiosensitization of human glioma lines in vitro Proc Am Assoc Clin Res 1997;38:45.
71. Shea WM, Dillman RO, Mahdavi K, Fong W, VanderMolen L, Barth N, Sheehy PF Radiotherapy with concurrent interferon alpha-2a and 13-cis-retinoic acid for treatment of high-grade malignant gliomas: a phase II trial of the National Biotherapy Study Group. Proc Am Soc Clin Oncol 1997;16:408a [abstr 1456]